
    
      Patients will be randomized, prospectively, single blinded into one of two arms:1)intravenous
      administration of Eptifibatide and 2) intracoronary administration. The primary end-point
      will be the angiographic achievement of TIMI 3 flow at the infarct related artery and TIMI
      myocardial perfusion grade (blush) and the electrocardiographic surrogate of myocardial
      perfusion the ST segment resolution.

      The secondary end-points will be the occurrence of bleeding or hemorrhagic complication
      according to TIMI classification and the LVEF at one month compared with baseline
    
  